Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2004 3
2005 4
2006 2
2007 4
2008 4
2009 6
2010 7
2011 8
2012 7
2013 11
2014 15
2015 17
2016 12
2017 12
2018 20
2019 15
2020 12
2021 6
2022 3
2023 9

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P; French Study Group on Autoimmune Bullous Diseases. Chen DM, et al. Among authors: quereux g. Br J Dermatol. 2020 May;182(5):1111-1119. doi: 10.1111/bjd.18482. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31487383 Free PMC article. Clinical Trial.
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Among authors: quereux g. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
[Paraneoplastic multicentric reticulohistiocytosis].
Nicol C, Quereux G, Renaut JJ, Renac F, Dreno B. Nicol C, et al. Among authors: quereux g. Ann Dermatol Venereol. 2011 May;138(5):405-8. doi: 10.1016/j.annder.2011.01.030. Epub 2011 Feb 26. Ann Dermatol Venereol. 2011. PMID: 21570566 Review. French.
Fotemustine for the treatment of melanoma.
Quéreux G, Dréno B. Quéreux G, et al. Expert Opin Pharmacother. 2011 Dec;12(18):2891-904. doi: 10.1517/14656566.2011.633513. Epub 2011 Nov 14. Expert Opin Pharmacother. 2011. PMID: 22077794 Review.
[Dacarbazine: deticene].
Quéreux G, Brocard A, Dréno B. Quéreux G, et al. Ann Dermatol Venereol. 2007 Dec;134(12):1001-3. doi: 10.1016/s0151-9638(07)78266-2. Ann Dermatol Venereol. 2007. PMID: 18166926 French. No abstract available.
[What’s new in dermato-oncology?].
Quéreux G. Quéreux G. Ann Dermatol Venereol. 2013 Nov;140 Suppl 3:S283-92. doi: 10.1016/S0151-9638(13)70144-3. Ann Dermatol Venereol. 2013. PMID: 24365500 Review. French.
Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French Study Group on Autoimmune Bullous Skin Diseases; Autoimmune Bullous Skin Disease Task Force of the European Academy of Dermatology and Venereology. Hébert V, et al. Among authors: quereux g. J Invest Dermatol. 2019 Jan;139(1):31-37. doi: 10.1016/j.jid.2018.04.042. Epub 2018 Oct 6. J Invest Dermatol. 2019. PMID: 30301637 Free article. Review.
Melanoma and rituximab: an incidental association?
Peuvrel L, Chiffoleau A, Quéreux G, Brocard A, Saint-Jean M, Batz A, Jolliet P, Dréno B. Peuvrel L, et al. Among authors: quereux g. Dermatology. 2013;226(3):274-8. doi: 10.1159/000350681. Epub 2013 Jul 9. Dermatology. 2013. PMID: 23941917 Review.
Incidence and Mortality of Pemphigus in France.
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D'incan M, Verneuil L, Litrowski N, Joly P; French Study Group on Autoimmune Blistering Diseases. Jelti L, et al. Among authors: quereux g. J Invest Dermatol. 2019 Feb;139(2):469-473. doi: 10.1016/j.jid.2018.07.042. Epub 2018 Sep 17. J Invest Dermatol. 2019. PMID: 30236611 Free article. No abstract available.
150 results